Targeted Radionuclide Boosts Survival in Pancreatic Tumors

[jayneesha]

In patients with inoperable progressive pancreatic cancer, a targeted radionuclide, lutetium-octreotate (OCLU), shows nearly double the 12-month progression-free survival (PFS) compared with sunitinib, researchers report. The findings come from the phase 2 OCLURANDOM trial, which investigated the antitumor efficacy of peptide receptor radionucleotide therapy (PRRT) with OCLU in previously treated patients with unresectable progressive pancreatic neuroendocrine tumors (NETs).

[bernipes]

@jayneesha This could change the practice treatment paradigm, with PRRT used prior to sunitinib in unresectable progressive advanced SSTR+ pancreatic NET patients, although ongoing randomized trials enrolling advanced patients will help to confirm these results